{
    "nctId": "NCT03586297",
    "briefTitle": "Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer",
    "officialTitle": "Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Pathologic Complete Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed new diagnosis of TNBC (\\<5% of ER and PR immunoreactivity and HER2- by FISH or IHC staining 0 or 1+)\n* \\>18 years\n* 1.5 cm mass lesion or greater\n* Tumor amenable to percutaneous core biopsy\n\nExclusion Criteria:\n\n* chronic anticoagulation therapy\n* prior ipsilateral breast surgery, ipsilateral radiotherapy, hormonal therapy or systemic chemotherapy\n* Prolonged antibiotic treatment \\> 10 days within 1 month of neoadjuvant chemotherapy as prevention or suppression of an ongoing infection\n* lactating\n* pregnant",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}